Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma is poised for strong growth, with a focus on developing and selling technically challenging generic and proprietary injectable products, as well as insulin API products. Despite competition in some segments, their recent launch has potential for significant sales growth. In 2026, the company anticipates high single-digit top-line growth and remains on track to achieve this goal.

Amphastar Pharma is facing pricing and competitive headwinds, particularly in their base generics business, with persistent issues including Baqsimi pricing headwinds resulting in top- and bottom-line misses for the second quarter in a row. The company is taking actions to improve the price point for Baqsimi, but the impact will linger, leading to a revision of sales growth expectations. Additionally, AMPH's top-line growth prospects are uncertain due to a lack of visibility and near-term catalysts such as new product approvals, with the company's majority revenue coming from the United States, China, and France.